» Articles » PMID: 35326796

Prescription Patterns of Drugs Given to Hospitalized COVID-19 Patients: A Cross-Sectional Study in Colombia

Abstract

The impact of COVID-19 prompted a race to find a treatment that would reduce its mortality. Most studies have not shown favorable results for many of these drugs, but they are still used. The aim as to determine the differences and similarities in the hospital pharmacological management of patients with COVID-19 according to sex, age group, and geographical region of Colombia, 2020-2021. Descriptive cross-sectional study was conducted on the prescription patterns of the medications given to patients diagnosed with COVID-19 treated in eight clinics in Colombia between 6 March 2020 and 31 May 2021. We performed a descriptive analysis of the sociodemographic, clinical, and pharmacological variables of the patients. A total of 8596 patients from 170 cities were identified, with a median age of 53.0 years and 53.3% of them men. A total of 24.3% required care in the intensive care unit, and 18.7% required invasive mechanical ventilation. The most commonly used drugs for the treatment of COVID-19 were systemic corticosteroids (63.6%), followed by colchicine (12.8%), azithromycin (8.9%), and ivermectin (6.4%). Corticosteroids, anticoagulants, colchicine, azithromycin, ivermectin, and hydroxychloroquine were prescribed more frequently in men, and their overall use increased with age. There were differences in prescriptions between geographic regions. The majority of patients were managed with medications included in the management guidelines. There were differences between sexes, age groups, and geographical regions.

Citing Articles

Adherence of Physicians to Local Guideline Recommendations among Patients with COVID-19 in Two Tertiary Public Hospitals in Metro Manila, Philippines: A Rapid Assessment Study.

Elepano A, Cordero C, Palileo-Villanueva L, Castillo-Carandang N, Abola M, Borbe J Acta Med Philipp. 2024; 57(11):34-40.

PMID: 39484058 PMC: 11522337. DOI: 10.47895/amp.vi0.6256.


Drug prescription patterns and their association with mortality and hospitalization duration in COVID-19 patients: insights from big data.

Mehrizi R, Golestani A, Malekpour M, Karami H, Nasehi M, Effatpanah M Front Public Health. 2024; 11:1280434.

PMID: 38164450 PMC: 10758044. DOI: 10.3389/fpubh.2023.1280434.


Use of Systemic Antibiotics in Patients with COVID-19 in Colombia: A Cross-Sectional Study.

Valladales-Restrepo L, Delgado-Araujo A, Echeverri-Martinez L, Sanchez-Rios V, Machado-Alba J Antibiotics (Basel). 2023; 12(2).

PMID: 36830163 PMC: 9952122. DOI: 10.3390/antibiotics12020252.

References
1.
Sun F, Kou H, Wang S, Lu Y, Zhao H, Li W . An analytical study of drug utilization, disease progression, and adverse events among 165 COVID-19 patients. Ann Transl Med. 2021; 9(4):306. PMC: 7944318. DOI: 10.21037/atm-20-4960. View

2.
Horby P, Lim W, Emberson J, Mafham M, Bell J, Linsell L . Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2020; 384(8):693-704. PMC: 7383595. DOI: 10.1056/NEJMoa2021436. View

3.
Diaz-Velez C, Urrunaga-Pastor D, Romero-Cerdan A, Pena-Sanchez E, Fernandez Mogollon J, Cossio Chafloque J . Risk factors for mortality in hospitalized patients with COVID-19 from three hospitals in Peru: a retrospective cohort study. F1000Res. 2021; 10:224. PMC: 8207806. DOI: 10.12688/f1000research.51474.1. View

4.
Serafim R, Povoa P, Souza-Dantas V, Kalil A, Salluh J . Clinical course and outcomes of critically ill patients with COVID-19 infection: a systematic review. Clin Microbiol Infect. 2020; 27(1):47-54. PMC: 7582054. DOI: 10.1016/j.cmi.2020.10.017. View

5.
Harapan H, Itoh N, Yufika A, Winardi W, Keam S, Te H . Coronavirus disease 2019 (COVID-19): A literature review. J Infect Public Health. 2020; 13(5):667-673. PMC: 7142680. DOI: 10.1016/j.jiph.2020.03.019. View